Leukocyte cell-derived chemotaxin-2 (LECT2) was originally identified as a hepatocyte-secreted chemokine-like factor and a positive target of β-catenin signaling. Here, we dissected out the mechanisms by which LECT2 modulates hepatocellular carcinoma (HCC) development using both HCC mouse models and human HCC samples. We have demonstrated that LECT2 exhibits dual abilities as it has profound repercussions on the tumor phenotype itself and the immune microenvironment. H epatocellular carcinoma (HCC) has emerged as the second leading cause of cancer-related death worldwide.
H epatocellular carcinoma (HCC) has emerged as the second leading cause of cancer-related death worldwide.
(1,2) HCC-related mortality is rapidly increasing in Western populations, with a minority of patients diagnosed at an early stage. Treatment options for HCC remain very limited, although the multikinase inhibitor sorafenib and more recently regorafenib have improved survival in advanced cases. (3) (4) (5) Our understanding of the molecular pathogenesis of HCC has recently progressed, providing an accurate picture of the landscape of genetic alterations in HCC. These studies have defined core pathways deregulated in HCC, with TP53 and CTNNB1 the most prevalent mutations after TERT promoter mutations. (6, 7) HCC is a model of inflammation-associated cancer, as inflammation is involved in all stages, from tumor initiation to progression and dissemination. (8) (9) (10) Indeed, several studies provided significant evidence regarding the predominant role of inflammatory signaling pathways (see He et al. (11) for review). Over the last 10 years, considerable attention has also focused on the concept of the tumor microenvironment (TME). (12) The TME is now recognized as a key actor in the carcinogenesis of most solid tumors. It plays a crucial role in liver cancer because more than 80% of HCCs emerge from a disrupted microenvironment. In several murine models of HCC, both innate and adaptive immune system components have been shown to participate in tumor development and progression, highlighting the intricate nature of the crosstalk between the immune system and tumor cells. (13) (14) (15) Approaches targeting TME composition are therefore considered an exciting prospect for HCC treatment.
In this context, we recently identified the chemokine-like factor leukocyte cell-derived chemotaxin-2 (Lect2) secreted by hepatocytes as a key player in the immune microenvironment during mouse liver tumorigenesis that controlled tumor aggressiveness. (16) In the present study, we evaluated LECT2 expression in a large human HCC data set and showed that HCC with lower LECT2 expression correlated with HCC of more advanced tumor grade and immune infiltrates. We further explored the role of Lect2 using our ß-catenin-induced HCC mouse model and found that it fosters a permissive immune microenvironment highly abundant in inflammatory monocytes able to sustain tumor growth and progression.
Materials and Methods

MICe
The different HCC mouse models used in the study that modeled HCC tumorigenesis were previously described in Anson et al. (16) The Lpk-myc+ transgenic mice, which express the oncogene c-myc gene in the liver under the control of rat L-PK regulatory regions, developed HCC mutated for Ctnnb1. (17) To obtain Ctnnb1-HCC deficient in Lect2, we crossed the Lpk-myc+ with Lect2 -/-mice. (18) HCC development was studied at 12 months in Lpk-myc+ and Lpk-myc+, Lect2 , Cre negative). (19, 20) Apc LKO mice were crossed with Lect2 -/-mice to generate mice with liver deficient in both Apc and Lect2 (Apc ). Inactivation of the Apc gene was done by a single intraperitoneal injection of 1.5 mg tamoxifen (MP Biomedicals, France) in 9-to 12-week-old mice. All mice were kept in well-controlled animal housing facilities and had free access to tap water and food pellets.
HUMaN lIVeR SaMpleS
A series of 243 liver tumor samples and corresponding nontumor liver samples were collected from 
NoNpaReNCHyMal Cell ISolatIoN
Nonparenchymal cells (NPC) were extracted from livers according to previously described method (16) using percoll gradient density (See Supporting Material). Red blood cells were removed by incubation with lysis buffer ACK (0.15 M NH 4 Cl, 10 mM KHCO 3 and 0.1 mM Na 2 EDTA, pH 7.2). Cells were resuspended in serum-containing medium and viable NPCs were counted by a trypan blue exclusion method, and stored on ice until further use.
FloW CytoMetRy aND Cell SoRtINg
Cells were incubated with anti-CD16/CD32 antibodies (Fcγ III/II receptor, clone 2.4G2, eBiosciences) before staining with labeled antibodies, according to the manufacturer's recommendations. Cells were subjected to fluorescence-activated cell sorting (FACS) analysis with specific antibodies (see Supporting Material). Data were acquired with an LSRII flow cytometer (BD Biosciences) and analyzed with FlowJo software (Tree Star Inc.). For functional and microarray analyses, hepatic myeloid cells were stained with specific antibodies and then sorted according to the marker combinations described in Fig. 4B , on an ARIA3 flow cytometer (BD Biosciences) with DIVA software (BD Biosciences). For microarrays, cells were sorted directly in the lysis buffer provided with the QIAGEN RNA extraction kit.
aNtIBoDy DepletIoN eXpeRIMeNt
Mice received a single intraperitoneal injection of 1.5 mg tamoxifen. Two days later, they received a single intraperitoneal injection of a cocktail of anti-Ccl2 (clone 2H5, Bio X Cell) antibody at a dose of 7.5 mg/kg and anti-Ccl5 antibody (clone 53405, R&D systems) at a dose of 1.0 mg/kg or control antibody (Polyclonal Armenian Hamster IgG, Bio X Cell; Normal Rat IgG control, R&D Systems). The efficacy of antibody depletion was evaluated by flow cytometry 8 days after tamoxifen injection.
t-Cell StIMUlatIoN
Naïve T cells sorted from the spleen of wild-type (WT) mice were labeled with 5 μM CellTrace Violet (CTV) (Molecular Probes, Life Technologies). Cells were washed and transferred to U-bottomed plates at a concentration of 2 × 10 4 cells per well. Each well was previously coated with 2 µg/mL anti-CD3ε antibody (clone 145-2C11, BD-Pharmingen), and 4 µg/mL soluble anti-CD28 antibody (clone 37.57, eBioscience) was added to stimulate T cells. Sorted myeloid cells from mouse tumors were added to the culture at a concentration of 4 × 10 3 cells per well. After 4 days in culture, T cells were stained for extracellular marker. Proliferation was assessed by evaluating the loss of CTV staining by flow cytometry.
pRIMaRy CUltURe oF HepatoCyteS
Primary mouse hepatocytes were isolated by in situ liver perfusion with a collagenase blend (SigmaAldrich). After isolation, cells were collected in complete medium (William's medium E supplemented with bovine serum albumin (0.1%), penicilin/streptomycin (100 U/mL), Fungizone B (100 g/mL), dexamethasone (25 nM), and insulin (4 g/mL). The hepatocytes were collected by three rounds of centrifugation for 3 minutes each at 400 rpm and resuspended in complete medium supplemented with 10% fetal bovine serum (FBS). Hepatocytes were counted by a trypan blue exclusion method, and their viability was found to be >90%. Cells were used to seed 60-mm plastic dishes (6 x 10 5 cells per plate) containing complete medium supplemented with 10% FBS, which were then incubated at 37°C under an atmosphere containing 5% CO 2 , for 4 hours, to allow the cells to adhere. The medium was then removed and replaced with fresh serum-free complete medium, or complete medium supplemented with 5 ng/mL TGF1 for stimulation. The cells were incubated for 36 hours. In coculture experiments, sorted myeloid cells from tumor mice were added at a density of 4 × 10 4 cells per dish to the hepatocyte primary culture until 48 hours.
IMMUNoHIStologICal StaININg
Immediately after mouse sacrifice, liver tissues were removed from the mouse and fixed by incubation in 4% formol overnight at 4°C for embedding in paraffin wax. Hematoxylin and eosin (H&E) staining was carried out on 3-m-thick paraffin sections. For immunohistochemistry, 5-m-thick sections were stained according to the procedure described in Supporting Material. Images were acquired with an Olympus BX63F microscope at ×4 and ×10 magnification, Uplan FLN objectives, an Olympus DP73 (CCD Bayer filter) camera, and Metamorph7.8.8.0 software (Molecular Devices).
IMMUNoFlUoReSCeNCe StaININg
For immunofluorescence staining, 7-m cryosections were stained according to the procedure described in Supporting Material. Images were acquired with an Olympus BX63F microscope at ×10 and ×40 magnification, with Uplan FLN objectives, a Hamamatsu ORCA-Flash4.0 LT C11440-42U (CMOS) camera, and Metamorph7.8.8.0 software (Molecular Devices).
IN SITU HyBRIDIZatIoN
In situ hybridization was performed on 10-m paraffin-embedded sections of liver tissue. Sections were deparaffinized and treated with proteinase K (5 g/ mL) in Tris/ethylene diamine tetraacetic acid (EDTA) buffer (1 M/0.5 M). Sections were washed in phosphate-buffered saline, treated with acetic acid (0.25%) and triethanolamine (0.10 M), and prehybridized by incubation for 2 hours at 68°C in saline-sodium buffer (2 M) with Denhardt's solution (100 g/mL), dextran sulfate (10%) and EDTA (0.05 M) before adding Afp-digoxygenin-labeled probes (sense 5'-CAT GGT CGA CGC CAT GAA GTG GAT CAC ACC C; antisense 5'-CAT GGT CGA CTT AAA CGC CCA AAG CAT CAC G) at a concentration of 500 ng/mL overnight at 68°C. Slides were washed once, for 5 minutes, in saline-sodium buffer (5 M) at 68°C; twice, for 30 minutes each, in saline-sodium buffer (0.2 M) at 68°C; and once for 5 minutes in saline-sodium buffer (0.2 M) at room temperature. Signals were detected with antidioxygenin antibody (Roche) and Nitro Blue Tetrazolium/5-bromo-4-chloro-3-indolyl phosphatate (Roche).
WeSteRN BlottINg
Protein extracts were prepared from nontumoral and tumoral liver samples by lysis in radio immunoprecipitation assay buffer supplemented with protease and phosphatase inhibitor cocktails (Roche Diagnostics). They were diluted in 2× Laemmli buffer (Sigma-Aldrich, S3401) and analyzed by western blotting, as previously described.
geNe eXpReSSIoN aNalySIS
Total RNA was extracted from frozen liver tissue or isolated hepatocytes with the RNeasy Mini Kit (Qiagen), according to the manufacturer's instructions. Total RNA was extracted from NPCs with the RNeasy Micro Kit (Qiagen), according to the manufacturer's instructions. Purified RNA was then reverse-transcribed with the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Real-time PCR was performed with the Fast Start SYBR green I Master kit (Roche) and a LightCycler 480 Instrument (Roche Applied Science). Gene expression was normalized relative to ribosomal 18s RNA levels. Expression levels in the various mouse liver samples were calculated for all genes, by the 2-delta-delta cycle qualification (Cq) method, and were compared with the level of expression of the corresponding gene in control liver tissues (expression as an n-fold ratio).
RNa Isolation and Microarray analysis
For the comparison of nodules, HCC/LECT2 knockout mice harboring differentiated and poorly differentiated nodules were selected on the basis of H&E staining on frozen sections. Differentiated and poorly differentiated nodules were macrodissected for each mouse, and total RNA was extracted in parallel from these two subsets with the RNeasy Mini Kit (Qiagen). For the comparison of myeloid cells, a micro RNeasy PLUS Kit (Qiagen) was used to extract total RNA from FACS-sorted myeloid cells. All RNA processing steps, microarrays, and statistical analysis were carried out by the Genom'IC facility (Institut Cochin, INSERM U1016, Paris, France). RNA quality was checked with a Bioanalyzer 2100 (with the Agilent RNA6000 pico chip kit), and 400 pg of total RNA was reverse-transcribed with Ovation Pico WTA System V2 (Nugen). The resulting double-stranded complementary DNA (cDNA) was used for amplification with Single Primer Isothermal Amplification (SPIA) technology. The DNA was purified according to the Nugen protocol, and 5 µg of sense target DNA was fragmented and labeled with biotin, with the Encore Biotin Module kit (Nugen). Fragmentation was checked on a Bioanalyzer 2100, and the cDNA was then hybridized to GeneChip MTA1.0 (Affymetrix) at 45°C for 17 hours. The chips were washed on an FS450 fluidic station, according to specific protocols (Affymetrix), and scanned with a GCS3000 7G. The scanned images were then analyzed with Expression Console software (Affymetrix) to obtain raw data (CEL Intensity files) and metrics for quality control. Observations of these metrics and the distribution of raw data revealed no outliers.
Data Submission
All the data obtained by microarray analysis have been deposited on the Gene Expression Omnibus NCBI site under accession number GSE 99570 and will be made available upon publication.
StatIStICal aNalySIS
Data are expressed as means ± standard deviation of the mean. Statistical significance was determined by two-way analysis of variance followed by a Student t test in Prism 6.0 software (GraphPad Software, San Diego, CA). We considered P values <0.05 to be statistically significant.
StUDy appRoVal
All reported animal procedures were carried out in accordance with the rules of the French Institutional Animal Care and Use Committee. All animal studies were approved by the regional veterinary services of the Paris police headquarters (agreement no. 75-956). For human samples, the study was approved by the relevant institutional review boards (CCPRB Paris Saint-Louis, 1997, 2004 and 2010, approval number 01-037; Bordeaux, 2010-A00498-31).
Results
loW leCt2 eXpReSSIoN IN HUMaN HCC IS StRoNgly aSSoCIateD WItH a HIgHeR tUMoR gRaDe aND tHe pReSeNCe oF INFlaMMatoRy INFIltRateS
We first investigated the clinical relevance of LECT2 during human liver tumorigenesis, by studying the levels of LECT2 mRNA in a large cohort of patients with HCC. We found that LECT2 expression was significantly downregulated in both benign and malignant hepatocellular tumors when compared with normal liver tissue (Fig. 1A) . We next assessed LECT2 expression according to the molecular classification of human HCC on the basis of clinical and genomic features. (21, 22) Groups G1 to G3 are characterized by chromosomal instability, whereas groups G4 to G6 are associated with chromosomal stability. We observed that LECT2 expression level was significantly lower in G1-G3 groups compared with G4-G6; G5-G6 harbored activating mutations into beta-catenin gene (CTNNB1) (Fig.  1B; Supporting Fig. S1 ). Importantly, we found that LECT2 expression was inversely correlated with tumor grade because highly malignant nodules classified as stage III to IV according to the EdmondsonSteiner classification showed a low expression of LECT2 (Fig. 1C) . In addition, we found that human HCCs with inflammatory infiltrates had the lowest levels of LECT2 (Fig. 1D ). This was corroborated by the strong correlation between the expression of LECT2 and IKBKE gene (Fig. 1E) .
Altogether, our findings showed that low LECT2 expression level in human HCC correlated with a more advanced histological grade and containing inflammatory infiltrates.
pooRly DIFFeReNtIateD NoDUleS aRISINg IN leCt2-DeFICIeNt HCC HaVe aN epItHelIal to MeSeNCHyMal tRaNSItIoN/pRogeNItoR/ MetaStaSIS SIgNatURe
We used the Lpk-myc + mouse model that developed Ctnnb1-mutated HCC of well-differentiated phenotype, overexpressing Lect2 (see Materials and Methods). We previously showed that the deletion of Lect2 in Lpk-myc + mice (Lpk-myc+, Lect2
-/-) elicited the development of heterogeneous tumors harboring different tumor grades including invasive HCC (16) (see Materials and Methods and Supporting Fig. S2A ).
To identify actors that participate in tumor aggressiveness in Lect2-deficient HCC, we compared the transcriptional profiles of macrodissected poorly differentiated nodules with those of well-differentiated adjacent nodules. Our results showed, in poorly differentiated tumors, signatures of cell invasiveness, extracellular matrix (ECM) remodeling, and immune response ( Fig. 2A; Supporting Fig. S2B ). Gene set enrichment analysis (GSEA) revealed an enrichment in genes relating to ECM and collagens, immune response, and angiogenesis ( Fig. 2B;  Supporting Fig. S2C ). Accordingly, reverse-transcription real-time quantitative PCR (RT-qPCR) analysis showed a strong up-regulation of markers linked to progenitor cell features, epithelial to mesenchymal transition (EMT) process, and TGFβ signaling (Fig. 2C ). Immunohistochemistry and in situ hybridization analyses showed that the poorly differentiated nodules up-regulated hepatic progenitor cell markers (Sox9, Afp) and down-regulated the hepatocyte differentiation marker Hnf4α (Fig. 2D) . Cell invasiveness and EMT were confirmed by immunofluorescence staining and western blot analysis. We found an up-regulation of the phosphorylated and active forms of c-Met and Smad2/3, an increase of Snail and N-Cadherin expression in the poorly differentiated nodules (Fig. 2E) . Invasiveness was also supported by PECAM-1 staining surrounding the poorly differentiated structures (Fig. 2E) .
Collectively, our data evidenced that the loss of Lect2 triggered the emergence of poorly differentiated HCC harboring progenitor cell traits and EMT features.
loSS oF leCt2 FoSteRS tHe aMplIFICatIoN oF INFlaMMatoRy MoNoCyteS IN HCC
Because Lect2 is an immune modulator, we analyzed the immune infiltrate in the vicinity of the poorly differentiated nodules that developed in Lect2-deficient HCC. Pan-CD45 immunofluorescence staining revealed that the immune infiltrate was predominantly located close to these structures and contained FIg. 1. Low LECT2 expression in human HCC is strongly associated with a higher tumor grade and the presence of inflammatory infiltrates. (A) Levels of LECT2 mRNA were determined in benign and malignant tumors. Benign = hepatocellular adenoma (n = 109); Malignant = HCC (n = 267). The fold change (log 2 ) in gene expression is presented relative to expression in NTL (n = 58), on the y axis. Error bars represent the SD. A significant difference in expression was defined as **P < 0.01, ***P < 0.001 in the Wilcoxon ranksum test. (B) Levels of LECT2 mRNA were assessed in liver tumor samples from patients, according to the molecular classification of HCC, and were compared with those for NTL. G1-G6 classification according to Laurent-Puig and Zucman-Rossi, 2006. G1-G3 (n = 84) are associated with chromosomal instability, whereas G4-G6 (n = 182) are associated with chromosomal stability. The fold change (log 2 ) in gene expression is presented relative to expression in NTL (n = 58), on the y axis. Error bars represent the SD. A significant difference in expression was defined as ****P < 0.0001 in the Wilcoxon rank-sum test. (C) Levels of LECT2 mRNA were assessed in HCCs classified according to Edmonson Steiner grade. Grade I-II = well-differentiated HCC (n = 122); Grade III-IV: poorly differentiated HCC (n = 143). The fold change (log 2 ) in gene expression is presented relative to expression in NL samples, on the y axis. Error bars represent the SD. A significant difference in expression was defined as *P < 0.05; ***P < 0.001 in the Wilcoxon rank-sum test. (D) Levels of LECT2 mRNA were assessed in HCCs classified according to the presence (n = 46) or not (n = 111) of inflammatory infiltrates (histological identification). The fold change (log 2 ) in gene expression is presented relative to expression in NTL, on the y axis. A significant difference in expression was defined as ***P < 0.001, ****P < 0.0001 in the Wilcoxon rank-sum test. (E) Correlation between the expression of LECT2 and IKBKE mRNA levels in human HCC samples (n = 513). Single values were plotted and the correlation was assessed by calculating Pearson's product-moment correlation coefficient. Statistical significance was assessed in Student t tests. Abbreviations: NL, normal liver; NTL, nontumor liver samples.
several F4/80-positive cells together with Gr1-positive cells and few T lymphocytes (β-TCR-positive cells) (Fig. 3A) . These results prompted us to characterize in detail the myeloid F4/80-positive populations in Lect2-deficient HCC, as these immune cells are critical players in solid tumor development and progression. (Fig. 3B) . Moreover, we found an increase in the proportion of cells expressing Ly6C marker among the F4/80 + CD11b
+ population of cells, defining these latter as inflammatory monocytes (Fig. 3B) .
Furthermore, we investigated chemokines and chemokine receptors expression to determine whether the loss of Lect2 modified chemotactic signals of the TME, favoring the attraction of inflammatory monocytes. We found that the major myeloid-related chemokines (Ccl2, Ccl5, Cx3cl1) were significantly higher in Lect2-deficient HCC compared with Lect2-proficient HCC (Fig. 3C) . Chemokine/growth factor receptors (Ccr2, Csf1r, Cx3cr1) were highly expressed by the inflammatory monocytes infiltrating Lect2-deficient HCC (Fig. 3D) .
Our data showed an amplification of inflammatory monocytes in Lect2-deficient HCC that might be recruited in response to chemotactic signals secreted by Lect2-deficient HCC cells.
tHe INFlaMMatoRy MoNoCyteS INFIltRatINg leCt2-DeFICIeNt HCC HaRBoR aN IMMatURe pHeNotype WItH IMMUNoSUppReSSIVe CapaCItIeS aND tUMoRpRoMotINg poteNtIal
Myeloid cells have been reported to act as pejorative immunosuppressive agents in many solid tumors and have been associated with poor patient outcome. (23) (24) (25) We thus characterized the inflammatory monocytes infiltrating Lect2-deficient HCC. We found that both the percentage and the relative expression level of several maturation markers (MHC II, CD1d, and the costimulatory molecule CD86) were lower in inflammatory monocytes from Lect2-deficient HCC compared with Lect2-proficient HCC (Fig. 4A) . Interestingly, we monitored the expression of CD209a, recently shown as a functional receptor for LECT2, (26) and found that it was expressed by the inflammatory monocytes (Fig. 4B) .
We assessed their immunosuppressive equipment by RT-qPCR analyses on cell-sorted inflammatory monocytes. In the absence of Lect2, inflammatory monocytes drastically up-regulated expression of Arg1, S100a8/S100a9, and IL-10, but no significant difference was observed for Nos2 (Fig. 4C) . We then tested functionally their suppressive potential against naïve T cells. Interestingly, inflammatory monocytes from Lect2-deficient HCC were able to impair the naïve T-cell proliferation triggered by specific anti-CD3 and anti-CD28 antibodies, whereas inflammatory monocytes isolated from Lect2-proficient HCC failed to do so (Fig. 4D) .
We next evaluated the tumor-promoting potential of inflammatory monocytes isolated from Lect2-deficient HCC by studying their genetic program by microarray analysis ( Fig. 5A; Supporting Fig. S3 ). GSEA highlighted significant enrichment in signatures linked to TGFβ and Vegf-A signaling as well as ECM and collagen (Fig. 5B) . Accordingly, we found by RT-qPCR analysis a strong upregulation of Veg fa, Mmp9, and Thbs1, which have been widely studied as major players in extracellular matrix remodeling and angiogenesis (Fig. 5C) . We then characterized their polarization status through expression of several cytokines and transcription factors. We observed a higher expression of both M1 (Il1β, Il6, Stat5a) and M2-like factors (Tg fβ1, Stat3, Ym1) in inflammatory monocytes of Lect2-deficient HCC (Fig. 5C) .
Finally, we benefited from our preneoplastic Apc LKO model that mimics the early steps of β-catenin-induced tumorigenesis (see Anson et al. (16) and Material and Methods). We found that the inflammatory monocyte population was also increased in Apc LKO and significantly more in liver of Apc LKO deficient in Lect2 (Fig. 6A) . However, the inflammatory monocytes isolated from liver of Lect2-deficient Apc LKO mice did not exhibit a drastic difference in terms of maturation markers and were not endowed with strong immunosuppressive equipment (Fig.  6B,C) . To confirm the role of the chemokines Ccl2 and Ccl5 identified in Lect2-deficient HCC for the recruitment of inflammatory monocytes, we used specific neutralizing antibodies in our Apc LKO mice. FACS analysis revealed that both the proportion and the number of inflammatory monocytes were significantly reduced when blocking antibodies were injected in Apc LKO mice (Fig. 6D,E) . Collectively, these data evidenced that Lect2 shapes the HCC immune microenvironment with a recruitment of immature inflammatory monocytes harboring immunosuppressive properties and tumor-promoting potential.
leCt2 DISplayS DUal FUNCtIoNS to CoNtRol aN eMt pRogRaM IN Β-CateNINaCtIVateD HepatoCyteS
Finally, according to the poorly differentiated tumor phenotype seen in the Lect2-deficient Lpk-myc mice, we investigated whether Lect2 could affect the EMT response of the tumor cells. EMT response was analyzed in vitro by measuring Zeb1, Snail1, and Tgfβ1 levels after Tgfb1 treatment of primary hepatocyte cultures isolated from Lect2-proficient and -deficient Apc LKO mice (Fig. 7A) . Strikingly, the EMT response was significantly higher in Lect2-deficient compared with Lect2-proficient hepatocytes in response to Tgfb1 stimulation (Fig. 7B) . Of note, Tgfb1-induced EMT response was not different between Lect2-deficient and WT primary hepatocytes, showing that Lect2 did not impact the Tgfb1-dependent EMT response without beta-catenin-activated condition (Supporting Fig. 4A,B) . These results suggested that Lect2, in a cell autonomous manner, kept down the EMT response in , and CTRL livers. *P < 0.05; **P < 0.01; ****P < 0.0001; error bars represent the SD. The data shown are representative of three independent experiments with three mice per group. (C) The expression of genes associated with myeloid cell chemotaxis was assessed by RT-qPCR in HCC and Lect2 -/-HCC livers. The data shown are representative of three independent experiments with three mice per group. *P < 0.05; **P < 0.01; error bars represent the SD. (D) The expression of genes associated with chemokine receptors was assessed by RT-qPCR in inflammatory monocytes sorted from HCC and Lect2 -/-HCC livers. The data shown are representative of two independent experiments with three mice per group. **P < 0.01; ****P < 0.0001; error bars represent the SD. Abbreviations: CTRL, control; ns, nonsignificant. 
Lect2
-/-HCC inflammatory monocytes are enriched in TGFβ, VEGFA ECM/collagen signatures. (C) The expression of genes encoding tumor-promoting factors, cytokines, and M1/M2 markers was assessed by RT-qPCR in inflammatory monocytes isolated from HCC and Lect2 -/-HCC livers. All data are representative of two independent experiments with three mice per group. **P < 0.01; ***P < 0.001; ****P < 0.0001; error bars represent the SD. Abbreviations: ES, enrichment score; FDR, false discovery rate; FWER, family-wise error rate.
β-catenin-activated hepatocytes. Because the inflammatory compartment can also control EMT in tumor cells, we further investigated the role of Lect2 in this phenomenon. Coculture experiments were used to test the ability of the inflammatory monocytes isolated from both deficient-and proficient-Lect2 HCC to induce EMT program on beta-catenin-activated hepatocytes (Fig. 7C) . Interestingly, inflammatory monocytes isolated from Lect2-deficient HCC were able to induce EMT program on Lect2-deficient Apc LKO hepatocytes, whereas inflammatory monocytes isolated from Lect2-proficient HCC failed to do so (Fig. 7D) . These results showed that loss of Lect2 conferred to the inflammatory monocytes the capacity to induce epithelial EMT in Lect2-deficient beta-catenin-activated hepatocytes.
Altogether, these findings showed that Lect2 curtailed EMT process in β-catenin-activated HCC by impacting both on the tumor cells and the immune microenvironment.
Discussion
HCC is a life-threatening disease for which current treatments are largely ineffective. (27) Therefore, there is an urgent need to develop new strategies for treating liver cancer. The extensive development of immunotherapy and the objective clinical results obtained with other tumor types (28) suggest that manipulation of the immune system should be considered a valuable treatment for HCC. (29) We previously identified the chemokine-like Lect2 in dialogue with liver natural killer T cells as a key actor that controls HCC tumor aggressiveness of β-catenin-activated HCC. (16) Here, we further explored the role of Lect2 per se and found that it could constitute a pertinent immune target for HCC treatment. In our cohort of patients with HCC, we demonstrated that the level of LECT2 inversely correlated with tumor grade and the presence of inflammatory infiltrates regardless of the CTNNB1 mutational status. Using dedicated β-catenin-activated HCC model, we showed that Lect2 controls the tumor progression by targeting both the hepatic immune microenvironment and tumoral hepatocytes. Indeed, we evidenced that Lect2 prevents the recruitment and the acquisition of immunosuppressive properties and EMT induction capacities of inflammatory monocytes. Moreover, we showed that Lect2 has the ability to keep down the EMT response in beta-catenin-activated hepatocytes. Thus, our results demonstrate that loss of Lect2 fosters a permissive immune microenvironment highly abundant in inflammatory monocytes able to sustain tumor growth and progression (Fig. 8) .
Interestingly, in most solid tumors, myeloid cells have been demonstrated as the major part of the immune cell infiltrates. (30) They support chronic inflammation, which is carcinogenic in itself, suppress anticancer immune responses, sustain tumor growth by neo-angiogenesis, and contribute to form niches that enable metastasis. (31, 32) The significance All data are representative of three independent experiments, with three mice per group for hepatocytes and six mice per group for inflammatory monocyte pools. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; error bars represent the SD. of macrophage infiltration of tumors is frequently demonstrated by its evaluation as a prognostic marker. In human liver tumorigenesis, their presence is consistently associated with a poor HCC prognosis. (23, 24, 33) Here, we extended these data and found that the loss of Lect2 polarizes inflammatory monocytes into immunosuppressive players able to provoke EMT in beta-catenin-activated hepatocytes. We identified that these cells express several factors known to act in synergy in cell differentiation, EMT, and metastasis, such as TGFβ and IL-6. (34, 35) These observations are supported by recent findings demonstrating the involvement of IL6 derived from tumor-associated macrophages in the promotion of human HCC. (36) Beyond the previously used M1/M2-based dichotomy, which per se cannot accurately recapitulate the phenotype and function of macrophages seen in vivo, (37, 38) our data revealed that Lect2 regulates the cytokine secretion profiles of inflammatory monocytes that in turn conditioned tumor hepatocyte fate. The important finding of our work is that Lect2 harbors both cell-autonomous and extrinsic properties during β-catenin-induced HCC. Indeed, the expression of EMT markers that we characterized in the poorly differentiated HCC developed in Lect2-deficient mice resulted from signals of the inflammatory compartment but also from the removal of an intrinsic brake controlled by Lect2 in the tumor cells. Based on this dual ability and based on the fact that EMT is connected to a pejorative tumorigenesis with drug resistance and immunosuppression, we defined Lect2 as a crucial actor that prevents tumor aggressiveness. In a recent study using HuH7 cell line, LECT2 was found to bind to c-Met receptor, turning off its signaling. (39) Our study corroborates these findings, as we found an activation of c-Met signaling in the poorly differentiated nodules of Lect2-deficient HCC livers but not in differentiated ones, emphasizing the complexity of Lect2 signaling in liver tumorigenesis. Therefore, how Lect2 impacts on hepatocyte is still an open question and remains to be investigated.
Recent data showed that LECT2 could be involved in vascular invasion in xenograft models (40) and an HCC cohort of Asian patients. (41) Our work supports these findings further, as we observed in both inflammatory monocytes and poorly differentiated structures in Lect2-deficient HCC an up-regulation of genes involved in angiogenesis/vascular remodeling. Moreover, we provided evidence that inflammatory monocytes from Lect2-deficient HCC livers expressed a high level of VEGFA. Collectively, our findings revealed that Lect2 curtailed EMT and angiogenesis processes in β-catenin-activated HCC by impacting both on the tumor cells and the immune microenvironment.
Finally, our work raises questions about HCC treatment to control the effects of infiltrating myeloid cells on HCC tumor cells. In terms of targeting myeloid cells during tumorigenesis, several approaches have been investigated, mostly in murine preclinical models, with various degrees of success depending on the tumor types and vascularization through the blockade of their recruitment or function. (42) Few clinical trials have been carried out on solid tumors in humans, but no data are currently available for human liver cancer. Targeting of these cells during liver tumorigenesis represents a future challenge. The re-education of myeloid cells in the tumor is currently considered a very promising approach. (43) It consists in the reprogramming of inflammatory monocytes/macrophages to limit their pro-tumoral potential. In this context, strategies designed to reintroduce Lect2 in preclinical HCC models could be interesting and should be tested.
Impacting on the crosstalk between tumor cells and inflammatory monocytes represents an important challenge to be met, as it would greatly attenuate liver tumor aggressiveness. In this context, LECT2 appears to be a promising immunotherapeutic option for the treatment of HCC.
